tbuckley/cabot-search huggingface dataset:
Enhanced support for adherence to rheumatic heart disease prophylaxis for children in the public health system in Uganda (CAMPS): a pragmatic randomised trial
Authors: Sarah de Loizaga, Jafesi Pulle, Okumu Atanas, Juliet Alepere, Jane-Liz Nambogo, Emma Ndagire, Gloria Kaudha, Nicholas J Ollberding, Emmy Okello, Joselyn Rwebembera, Andrea Beaton
Journal: The Lancet Global Health (2025)
Causes of hospitalisation among people living with HIV worldwide, 2014–23: a systematic review and meta-analysis
Authors: Rachael M Burke, Nadia Sabet, Jayne Ellis, Ajay Rangaraj, David S Lawrence, Joseph N Jarvis, Jane Falconer, Lillian Tugume, Gabriella Bidwell, Rebecca H Berhanu, Peter MacPherson, Nathan Ford
Journal: The Lancet HIV (2025)
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
Authors: Marc Scherlinger, Gaetane Nocturne, Marko Radic, David Launay, Christophe Richez, Philippe Bousso, Edouard Forcade, Alain Meyer, Christian Jorgensen, Camille Bigenwald, Divi Cornec, Jean Sibilia, Sylvain Choquet, Thierry Martin, Alexandre Belot, Maurine Jouret, Samuel Bitoun, Zahir Amoura, Olivier Hermine, Xavier Mariette, Emmanuel Donnadieu, Jérome Avouac
Journal: The Lancet Rheumatology (2025)
Selective vascular disrupting therapy by lipid nanoparticle-mediated Fas ligand silencing and stimulation of STING
Authors: Rikito Endo, Tomoki Ueda, Takumi Nagaoki, Yusuke Sato, Nako Maishi, Kyoko Hida, Hideyoshi Harashima, Takashi Nakamura
Journal: Biomaterials (2025)
Nanozyme‐Shelled Microcapsules for Targeting Biofilm Infections in Confined Spaces (Adv. Healthcare Mater. 8/2025)
Authors: Hong Huy Tran, Nadasinee Jaruchotiratanasakul, Zhenting Xiang, Nil Kanatha Pandey, Min Jun Oh, Yuan Liu, Zhi Ren, Alaa Babeer, Michael J. Zdilla, David P. Cormode, Bekir Karabucak, Daeyeon Lee, Edward B. Steager, Hyun Koo
Journal: Advanced Healthcare Materials (2025)
Orally Deliverable Iron‐Ceria Nanotablets for Treatment of Inflammatory Bowel Disease (Adv. Healthcare Mater. 8/2025)
Authors: Seungmin Baik, Hyunmin Kim, Yunjung Lee, Taegyu Kang, Kwangsoo Shin, Changyeong Song, Ok Kyu Park, Byeonggeun Kang, Nohyun Lee, Dokyoon Kim, Seung Hong Choi, Seung Han Kim, Min Soh, Taeghwan Hyeon, Chi Kyung Kim
Journal: Advanced Healthcare Materials (2025)
Peroral endoscopic myotomy for symptomatic blown-out myotomy following previous myotomy for achalasia
Authors: Zhao-Chao Zhang, Jia-Qi Xu, Hai-Ting Pan, Xin-Yang Liu, Shi-Yao Chen, Yun-Shi Zhong, Yi-Qun Zhang, Li-Li Ma, Jian-Wei Hu, Ming-Yan Cai, Wen-Zheng Qin, Quan-Lin Li, Wei-Feng Chen, Ping-Hong Zhou
Journal: Endoscopy (2025)

Blown-out myotomy (BOM) may impair the discharge of esophageal contents, leading to recurrent symptoms following myotomy. This study aimed to evaluate the safety and effectiveness of salvage peroral endoscopic myotomy (POEM) for symptomatic BOM.Between August 2011 and August 2022, 77 patients with recurrent achalasia with BOM and 168 with recurrent achalasia without BOM underwent POEM and were retrospectively enrolled. Operation-related parameters were compared between the two groups.Salvage POEM was performed in patients with symptomatic BOM, with a mean procedure duration of 60.8 minutes. The mean hospital stay was 3.2 days. Procedure-related adverse events included 16 cases (20.8%) of Type I mucosal injury, 3 cases (3.9%) of Type II mucosal injury, 5 cases (6.5%) of pneumothorax, 2 cases (2.6%) of emphysema, and 2 cases (2.6%) of pneumoperitoneum. Three patients (3.9%) experienced major adverse events. No statistically significant differences were found between the two groups in the incidence of mucosal injury, gas-related adverse events, and major adverse events. Clinical success was equivalent between the two groups at the 2-year follow-up (85.7% vs. 92.3%; P = 0.16).Based on this study, POEM could be considered as an effective treatment option for patients with symptomatic BOM.
Double Enzyme Active Hydrogel Program Regulates the Microenvironment of <i>Staphylococcus aureus</i>‐Infected Pressure Ulcers (Adv. Healthcare Mater. 8/2025)
Authors: Hailin Xie, Yuna Qian, Jiayi Ding, Rui Zhao, Linwei Huang, Jianliang Shen, Zhihua Zhou
Journal: Advanced Healthcare Materials (2025)
A rare mediastinal mass treated by submucosal tunneling endoscopic resection
Authors: Weizhao Wang, Mengxian Ju, Jun Liu, Pinghong Zhou, Lu Wang, Chaowu Chen, Chao Sun
Journal: Endoscopy (2025)

A 46-year-old man presented with a sensation of obstruction during eating and gastroscopy revealed a submucosal mass in the lower esophagus. The mass was located about 35–38 cm from the incisors, had a smooth surface, and measured 3.0 × 5.0 cm ([Fig. 1]). Endoscopic ultrasound examination revealed a hypoechoic mass protruding into the esophageal and mediastinal cavities, which was poorly demarcated from the muscularis propria, and was considered to have originated from either the muscularis propria or the mediastinum as a space-occupying lesion ([Fig. 2]). A enhanced computed tomography scan showed a hypodense mass of homogeneous density adjacent to the lower esophagus, about 3.0 cm in diameter, poorly demarcated from the esophagus and mediastinum, with unremarkable enhancement ([Fig. 3]). The patient's full blood count, liver, renal, and coagulation function, and tumor markers were within reference values. The preoperative diagnosis was of "submucosal tumor of the esophagus" or "mediastinal occupation." Endoscopic resection (submucosal tunneling endoscopic resection [STER]) was performed after obtaining consent from the patient.
Endoscopic ultrasound-guided antegrade treatment using a novel nonslip short-length balloon catheter for hepaticojejunostomy anastomotic stricture
Authors: Tadahisa Inoue, Rena Kitano, Tomoya Kitada, Kazumasa Sakamoto, Satoshi Kimoto, Jun Arai, Kiyoaki Ito
Journal: Endoscopy (2025)

Balloon stricture dilation via balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography is the standard treatment for hepaticojejunostomy anastomotic stricture (HJAS) [1], but accessing the anastomosis is often challenging. In such cases, an endoscopic ultrasound (EUS)-guided antegrade approach can be considered as an alternative.
Peroral endoscopic tunneling under saline combined with partial myotomy for hypercontractile esophagus
Authors: Georgios Mavrogenis, Alexandros Ioannou, Thanassis Karamountzos, George Karamanolis
Journal: Endoscopy (2025)

Underwater peroral endoscopic myotomy was initially presented as an alternative approach for the treatment of achalasia, with only a few case reports published since its initial description [1] [2] [3] [4]. The theoretical advantage of using saline infusion instead of carbon dioxide is the diminished risk of gas-related events such as capnoperitoneum, tension pneumothorax, or pneumomediastinum. However, in our experience, the major advantage of working under saline is the stabilization of the endoscope in the setting of increased esophageal motility. The purpose of this video ([Video 1]) is to illustrate the advantages of performing peroral endoscopic tunneling under saline combined with partial myotomy in the setting of hypercontractile esophagus.
An upgraded rotatable sphincterotome enhances bile duct cannulation via balloon endoscopy-assisted endoscopic retrograde cholangiopancreatography
Authors: Yuya Takenaka, Katsuyuki Miyabe, Toshitaka Mori, Naoki Atsuta, Yasuki Hori, Tomonori Yamada, Kazuki Hayashi
Journal: Endoscopy (2025)

Bile duct cannulation via balloon endoscopy-assisted endoscopic retrograde cholangiopancreatography (ERCP) can be challenging, particularly in complex anatomical scenarios [1] [2]. This case report emphasizes the clinical application of a novel rotatable sphincterotome in a 75-year-old man who presented to a local clinic with a 1-week history of bilirubinuria. The patient had a history of gastric cancer and had undergone a distal gastrectomy with Roux-en-Y reconstruction 6 years previously. Laboratory tests revealed elevated liver enzymes, prompting a referral to our hospital. Contrast-enhanced computed tomography and magnetic resonance cholangiopancreatography revealed mild common bile duct wall thickening and stricture with upstream biliary dilation ([Fig. 1], [Fig. 2]), which was eventually diagnosed as recurrent gastric cancer 6 months after ERCP.
DNA methylation memory of pancreatic acinar-ductal metaplasia transition state altering Kras-downstream PI3K and Rho GTPase signaling in the absence of Kras mutation
Authors: Emily K.W. Lo, Adrian Idrizi, Rakel Tryggvadottir, Weiqiang Zhou, Wenpin Hou, Hongkai Ji, Patrick Cahan, Andrew P. Feinberg
Journal: Genome Medicine (2025)

A critical area of recent cancer research is the emergence of transition states between normal and cancer that exhibit increased cell plasticity which underlies tumor cell heterogeneity. Pancreatic ductal adenocarcinoma (PDAC) can arise from the combination of a transition state termed acinar-to-ductal metaplasia (ADM) and a gain-of-function mutation in the proto-oncogene KRAS. During ADM, digestive enzyme-producing acinar cells acquire a transient ductal epithelium-like phenotype while maintaining their geographical acinar organization. One route of ADM initiation is the overexpression of the Krüppel-like factor 4 gene (KLF4) in the absence of oncogenic driver mutations. Here, we asked to what extent cells acquire and retain an epigenetic memory of the ADM transition state in the absence of oncogene mutation. We profiled the DNA methylome and transcriptome of KLF4-induced ADM in transgenic mice at various timepoints during and after recovery from ADM. We validated the identified DNA methylation and transcriptomic signatures in the widely used caerulein model of inducible pancreatitis. We identified differential DNA methylation at Kras-downstream PI3K and Rho/Rac/Cdc42 GTPase pathway genes during ADM, as well as a corresponding gene expression increase in these pathways. Importantly, differential methylation persisted after gene expression returned to normal. Caerulein exposure, which induces widespread digestive system changes in addition to ADM, showed similar changes in DNA methylation in ADM cells. Regions of differential methylation were enriched for motifs of KLF and AP-1 family transcription factors, as were those of human pancreatic intraepithelial neoplasia (PanIN) samples, demonstrating the relevance of this epigenetic transition state memory in human carcinogenesis. Finally, single-cell spatial transcriptomics revealed that these ADM transition cells were enriched for PI3K pathway and AP1 family members. Our comprehensive study of DNA methylation in the acinar-ductal metaplasia transition state links epigenetic memory to cancer-related cell plasticity even in the absence of oncogenic mutation.
Pamoic acid and carbenoxolone specifically inhibit CRISPR/Cas9 in bacteria, mammalian cells, and mice in a DNA topology-specific manner
Authors: Yuxuan Zhang, Wentao Zou, Yueyang Zhou, Jiaqi Chen, Youtian Hu, Fang Wu
Journal: Genome biology (2025)

Regulation of the target DNA cleavage activity of CRISPR/Cas has naturally evolved in a few bacteria or bacteriophages but is lacking in higher species. Thus, identification of bioactive agents and mechanisms that can suppress the activity of Cas9 is urgently needed to rebalance this new genetic pressure. Here, we identify four specific inhibitors of Cas9 by screening 4607 compounds that could inhibit the endonuclease activity of Cas9 via three distinct mechanisms: substrate-competitive and protospacer adjacent motif (PAM)-binding site-occupation; substrate-targeting; and sgRNA-targeting mechanisms. These inhibitors inhibit, in a dose-dependent manner, the activity of Streptococcus pyogenes Cas9 (SpyCas9), Staphylococcus aureus Cas9 (SauCas9), and SpyCas9 nickase-based BE4 base editors in in vitro purified enzyme assays, bacteria, mammalian cells, and mice. Importantly, pamoic acid and carbenoxolone show DNA-topology selectivity and preferentially inhibit the cleavage of linear DNA compared with a supercoiled plasmid. These pharmacologically selective inhibitors and new mechanisms offer new tools for controlling the DNA-topology selective activity of Cas9.
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Authors: Rik Ossenkoppele, Gemma Salvadó, Shorena Janelidze, Alexa Pichet Binette, Divya Bali, Linda Karlsson, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Erik Stomrud, Joseph Therriault, Nesrine Rahmouni, Pedro Rosa-Neto, Emma M. Coomans, Elsmarieke van de Giessen, Wiesje M. van der Flier, Charlotte E. Teunissen, Erin M. Jonaitis, Sterling C. Johnson, Sylvia Villeneuve, Tammie L. S. Benzinger, Suzanne E. Schindler, Randall J. Bateman, James D. Doecke, Vincent Doré, Azadeh Feizpour, Colin L. Masters, Christopher Rowe, Heather J. Wiste, Ronald C. Petersen, Clifford R. Jack, Oskar Hansson
Journal: Nature Aging (2025)

Plasma p-tau217 and tau positron emission tomography (PET) are strong prognostic biomarkers in Alzheimer's disease (AD), but their relative performance in predicting future cognitive decline among cognitively unimpaired (CU) individuals is unclear. In a head-to-head comparison study including nine cohorts and 1,474 individuals, we show that plasma p-tau217 and medial temporal lobe tau-PET signal display similar associations with cognitive decline on a global cognitive composite test (R2PET = 0.34 versus R2plasma = 0.33, Pdifference = 0.653) and with progression to mild cognitive impairment (hazard ratio (HR)PET = 1.61 (1.48-1.76) versus HRplasma = 1.57 (1.43-1.72), Pdifference = 0.322). Combined plasma and PET models were superior to the single-biomarker models (R2 = 0.35, P < 0.01). Sequential selection using plasma phosphorylated tau at threonine 217 (p-tau217) and then tau-PET reduced the number of participants required for a clinical trial by 94%, compared to a 76% reduction when using plasma p-tau217 alone. Thus, plasma p-tau217 and tau-PET showed similar performance for predicting future cognitive decline in CU individuals, and their sequential use enhances screening efficiency for preclinical AD trials.
Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade
Authors: Xavier Catena, Marta Contreras-Alcalde, Naiara Juan-Larrea, Daniela Cerezo-Wallis, Tonantzin G. Calvo, Cynthia Mucientes, David Olmeda, Javier Suárez, Sergio Oterino-Sogo, Lola Martínez, Diego Megías, David Sancho, Cristina Tejedo, Susana Frago, Diana Dudziak, Athanasios Seretis, Patrizia Stoitzner, María S. Soengas
Journal: Nature Cancer (2025)
Progression of Kidney Fibrosis after Sepsis
Authors: Charles de Roquetaillade, Manon Durand, Victor Beaucoté, Jérémie Guillemin, Christos Evangelos Chadjichristos, Antoine Roquilly, Benjamin Glenn Chousterman
Journal: Journal of the American Society of Nephrology (2025)

Abstract Sepsis is a life-threatening condition affecting each year an estimated 49 million people and causing 11 million deaths. Short-term mortality of sepsis was substantially reduced during the past decades and is still improving. Besides its short-term lethality, awareness regarding long-term consequences of sepsis is rising. Among all organs affected during sepsis, the kidney is the most vulnerable. Up to 40% of patients suffering from sepsis develop acute kidney injury (AKI), and sepsis is the leading cause of AKI among critically ills. Half of patients will recover from AKI during their stay; however, several studies have pointed out that those patients were at increased risk for the development of subsequent chronic kidney disease (CKD). In patients suffering from transient AKI, a second injury was found to hasten renal fibrogenesis. Taken together those findings challenge the concept of ad integrum recovery and strongly suggest maladaptive repair AKI, together with profound and durable alterations at intra-organ level. Factors driving AKI to CKD after sepsis are poorly understood and could be of multiple origins. Kidney macrophages have pleiotropic roles in health and disease. Following sepsis, a proportion of kidney macrophages undergoes pyroptosis in an “altruist” maneuver to recruit inflammatory cells. Empty niches are later colonized by circulating monocyte arising from bone marrow in a process called emergency myelopoiesis but also by expansion of resident cells. The role of monocytes and macrophages in the acute phase of sepsis is well described, however, their role in the resolution of inflammation is just beginning to be understood. In the present review, we will discuss the fate of kidney resident macrophages and recruited monocytes in septic AKI. We will review the evidence linking changes in the immune landscape and maladaptive repair after sepsis. Finally, we will consider how targeting macrophage recruitment and polarization might influence sepsis long-term consequences.
The serine protease KLK7 promotes immune cell infiltration in visceral adipose tissue in obesity
Authors: Aleix Ribas-Latre, Anne Hoffmann, Claudia Gebhardt, Juliane Weiner, Lilli Arndt, Nora Raulien, Martin Gericke, Adhideb Ghosh, Kerstin Krause, Nora Klöting, Paul T Pfluger, Bilal N Sheikh, Thomas Ebert, Anke Tönjes, Michael Stumvoll, Christian Wolfrum, Matthias Blüher, Ulf Wagner, Joan Vendrell, Sonia Fernández-Veledo, John T Heiker
Journal: Metabolism (2025)

Obesity is a major health problem associated with global metabolic dysfunction and increased inflammation. It is thus critical to identify the mechanisms underlying the crosstalk between immune cells and adipose tissue that drive cardiovascular and metabolic dysfunction in obesity. Expression of the kallikrein-related serine protease 7 (KLK7) in adipose tissue is linked to inflammation and insulin resistance in high fat diet (HFD)-fed mice. Here, we engineered mice with a macrophage-specific KLK7 knockout (KLK7MKO) to investigate how KLK7 loss impacts immune cell function and obesity-related pathology. Compared to control mice, we observed lower levels of systemic inflammation, with less infiltration and activation of inflammatory macrophages in HFD-fed KLK7MKO mice, particularly in the epididymal adipose tissue. Mechanistically, we uncover that Klk7 deficiency reduces pro-inflammatory gene expression in macrophages and restricts their migration through higher cell adhesion, hallmark features of macrophages in obese conditions. Importantly, through analyses of 1143 human visceral adipose tissue samples, we uncover that KLK7 expression is associated with pathways controlling cellular migration and inflammatory gene expression. In addition, serum KLK7 levels were strongly correlated with circulating inflammatory markers in a second cohort of 60 patients with obesity and diabetes. Our work uncovers the pro-inflammatory role of KLK7 in controlling inflammatory macrophage polarization and infiltration in visceral obesity, thereby contributing to metabolic disease. Thus, targeting KLK7 to control immune cell activation may dissociate adipose dysfunction from obesity, thereby representing an alternative obesity therapy.
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trial
Authors: Gottfried Schlaug, Christy Cassarly, Jody A Feld, Steve L Wolf, Veronica T Rowe, Stacy Fritz, Pratik Y Chhatbar, Anant Shinde, Zemin Su, Joseph P Broderick, Richard Zorowitz, Oluwole Awosika, Dylan Edwards, Chen Lin, Gerard E Franciso, George F Wittenberg, Svetlana Pundik, Christopher Gregory, Michael R Borich, Viswanathan Ramakrishnan, Wuwei Feng
Journal: The Lancet Neurology (2025)
Effectiveness of intrapartum azithromycin to prevent infections in planned vaginal births in low-income and middle-income countries: a post-hoc analysis of data from a multicentre, randomised, double-blind, placebo-controlled trial
Authors: Waldemar A Carlo, Alan T N Tita, Janet L Moore, Musaku Mwenechanya, Elwyn Chomba, Jennifer J Hemingway-Foday, Avinash Kavi, Mrityunjay C Metgud, Shivaprasad S Goudar, Richard J Derman, Adrien Lokangaka, Antoinette Tshefu, Melissa Bauserman, Jackie K Patterson, Poonam Shivkumar, Manju Waikar, Archana Patel, Patricia L Hibberd, Paul Nyongesa, Fabian Esamai, Osayame Austine Ekhaguere, Sherri Bucher, Saleem Jessani, Shiyam Sunder Tikmani, Sarah Saleem, Robert L Goldenberg, Sk Masum Billah, Ruth Lennox, Rashidul Haque, William Petri, Manolo Mazariegos, Nancy F Krebs, Denise C Babineau, Elizabeth M McClure, Marion Koso-Thomas
Journal: The Lancet Global Health (2025)
Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes
Authors: James A Berkley, Judd L Walson, Glenda Gray, Fiona Russell, Zulfiqar Bhutta, Per Ashorn, Shane A Norris, Ebunoluwa A Adejuyigbe, Rebecca Grais, Bernhards Ogutu, Jun Zhang, Guillermo L Chantada, Sharon Nachman, Edward Kija, Fyezah Jehan, Carlo Giaquinto, Nigel C Rollins, Martina Penazzato
Journal: The Lancet Global Health (2025)
Advancing maternal and perinatal health through clinical trials: key insights from a WHO global consultation
Authors: Teesta Dey, Mariana Widmer, Arri Coomarasamy, Shivaprasad S Goudar, Mabel Berrueta, Estela Coutinho, Myriam El Gaaloul, Ruth R Faden, A Metin Gülmezoglu, G Justus Hofmeyr, Marian Knight, Smaragda Lamprianou, Anna C Mastroianni, Flor M Munoz, Olufemi T Oladapo, Martina Penazzato, Françoise Renaud, Claire L Townsend, Mercedes Bonet
Journal: The Lancet Global Health (2025)
The effect of a social network-based intervention to promote HIV testing and linkage to HIV services among fishermen in Kenya: a cluster-randomised trial
Authors: Carol S Camlin, Lila A Sheira, Zachary A Kwena, Edwin D Charlebois, Kawango Agot, James Moody, Benard Ayieko, Sarah A Gutin, Antony Ochung, Phoebe Olugo, Jayne Lewis-Kulzer, Holly Nishimura, Monica Gandhi, Elizabeth A Bukusi, Harsha Thirumurthy
Journal: The Lancet Global Health (2025)
Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35: a modelling study
Authors: Tom Loosli, Nuri Han, Anthony Hauser, Johannes Josi, Suzanne M Ingle, Ard van Sighem, Linda Wittkop, Janne Vehreschild, Francesca Ceccherini-Silberstein, Gary Maartens, M John Gill, Caroline A Sabin, Leigh F Johnson, Richard Lessells, Huldrych F Günthard, Matthias Egger, Roger D Kouyos
Journal: The Lancet Global Health (2025)
Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice
Authors: Nina Gobat, Catherine Slack, Stacey Hannah, Jessica Salzwedel, Georgia Bladon, Juan Garcia Burgos, Becky Purvis, Barbara Molony-Oates, Nandi Siegfried, Phaik Yeong Cheah, Magda Conway, Dorcas Kamuya, Alun Davies, Tian Johnson, Martha Tholanah, Stephen Mugamba, Naigaga Lillian Mutengu, Shingai Machingaidze, Lisa Schwartz, Lembit Rägo, Kai von Harbou
Journal: The Lancet Global Health (2025)